Gregory Winger, MD
Family Medicine · St George, UTNPI 1235661745
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,000 of the $5,200 with a category attached, or 76.9%. It is spread thinly across 37 manufacturers, the largest accounting for just 23.6% — the pattern of someone who eats at a lot of different presentations.
Across 252 payments — averaging $20.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceuticals, Inc.$1K
- AbbVie$1K
- Amgen$397
- Lilly USA, LLC$361
- Boehringer Ingelheim$306
- Pfizer$253
- plus $2K from 31 others
Across 10 payments — averaging $7036.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$70K
What the payments were for
- Consulting fees$1,20023%
- Food & beverage$4,00077%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceuticals, Inc. | 3 | $1,228 |
| AbbVie | 67 | $1,041 |
| Amgen(2 entities) | 22 | $397 |
| Lilly USA, LLC | 36 | $361 |
| Boehringer Ingelheim | 19 | $306 |
| Pfizer | 15 | $253 |
| AstraZeneca | 12 | $208 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $152 |
| Boston Scientific | 6 | $142 |
| GSK | 9 | $138 |
| Johnson & Johnson | 7 | $127 |
| Novartis | 5 | $108 |
| Merck | 5 | $79 |
| Sumitomo Pharma America, Inc. | 3 | $66 |
| Sanofi Pasteur Inc. | 2 | $56 |
| Organon | 3 | $48 |
| Jazz Pharmaceuticals Inc. | 2 | $47 |
| Novo Nordisk | 3 | $45 |
| Lucid Diagnostics Inc. | 2 | $45 |
| Exact Sciences | 3 | $44 |
| Axsome Therapeutics, Inc. | 2 | $33 |
| Nevro Corp. | 2 | $31 |
| Sanofi-aventis U.S. LLC | 1 | $27 |
| Grifols USA, LLC | 1 | $22 |
| Aimmune Therapeutics, Inc. | 1 | $22 |
| Galderma Laboratories, L.p. | 1 | $18 |
| RGH Enterprises LLC | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Dexcom, Inc. | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Harmony Biosciences LLC | 1 | $14 |
| Optinose US, Inc. | 1 | $13 |
| Neurelis, Inc. | 1 | $13 |
| Medtronic | 1 | $12 |
| Daiichi Sankyo Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,200
How this compares
$5,200 in reported general payments places this provider in the 85th percentile of 928 family medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 142 | $177,662 |
| TrulicityDulaglutide | 35 | $65,076 |
| XareltoRivaroxaban | 29 | $45,008 |
| JardianceEmpagliflozin | 18 | $32,263 |
| OzempicSemaglutide | 20 | $20,571 |
| MyrbetriqMirabegron | 31 | $19,366 |
| LinzessLinaclotide | 20 | $14,493 |
| MounjaroTirzepatide | 13 | $13,684 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $13,396 |
| SymbicortBudesonide/Formoterol Fumarate | 32 | $9,746 |
| Atorvastatin Calcium | 674 | $6,745 |
| Repatha SureclickEvolocumab | 12 | $6,617 |
| Levothyroxine Sodium | 595 | $6,178 |
| Adderall XrDextroamphetamine/Amphetamine | 12 | $5,847 |
| Celecoxib | 165 | $5,541 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $253 | $177,662142 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $361 | $78,76048 claims |
| Johnson & JohnsonXarelto | $127 | $45,00829 claims |
| Boehringer IngelheimJardiance | $306 | $32,26318 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $208 | $26,06059 claims |
| Novo NordiskOzempic | $45 | $20,57120 claims |
| AbbVieLinzess | $1,041 | $14,49320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 928 family medicine providers in Utah.
Other family medicine in St George
- Douglas CallahanSt George$13K
- Michael CobbleSandy$1.3M
- Thomas ClarkProvidence$332K
- Courtney NelsonLayton$190K
- David ButtersLayton$189K
- Scott EricksonBountiful$101K
- Mark CacciamaniSalt Lake City$43K
- Clint MowerLehi$41K
- Russell AndersonTooele$30K
- Kirk OdonnellSalt Lake City$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.